Arvinas, Inc. announced on February 15, 2024, Sean Cassidy indicated that he would step down as Treasurer and principal financial officer of the company, effective February 29, 2024, to pursue another professional opportunity. On February 19, 2024, the board of directors of the company appointed Randy Teel, Ph.D., the Company's current Senior Vice President, Corporate and Business Development, to serve as the Treasurer and principal financial officer, effective February 29, 2024, while the Company undertakes a search to identify the Company's next permanent Chief Financial Officer, Treasurer and principal financial officer. Dr. Teel, age 45, has served as the Company's Senior Vice President, Corporate and Business Development since September 2021 and will also continue in those roles where he is responsible for the Company's corporate strategy, business development, investor relations, and communications functions.

From May 2018 to September 2021, Dr. Teel served as the Company's Vice President of Corporate Development. Prior to his time at the Company, from March 2015 to December 2017, Dr. Teel was Vice President and Head of Strategy at Alexion Pharmaceuticals, Inc. (Alexion"), where he was responsible for long-range planning, partnering with the R&D and Commercial organizations as they developed inline and lifecycle management strategies. While at Alexion, Dr. Teel also led enterprise risk management and numerous strategic initiatives across the company.

Prior to Alexion, from January 2008 to March 2015, Dr. Teel was an Associate Partner at McKinsey & Company, where he advised biopharmaceutical clients on issues in commercial, medical, and development. Dr. Teel received his B.Sc. in Biology at Gonzaga University and his Ph.D. in Immunobiology from Yale University.